Loading…
enGene Therapeutics Inc. is projected to rise to $2.55 by 2027, a +42% move from its current price of $1.79. ENGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.74 | $1.79 | $1.84 | +0.03% |
| Aug 5 | $1.72 | $1.79 | $1.86 | +0.07% |
| Aug 6 | $1.71 | $1.79 | $1.88 | +0.10% |
| Aug 7 | $1.70 | $1.79 | $1.89 | +0.14% |
| Aug 8 | $1.69 | $1.79 | $1.91 | +0.17% |
| Aug 9 | $1.68 | $1.79 | $1.92 | +0.21% |
| Aug 10 | $1.67 | $1.79 | $1.93 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.67 | $1.79 | $1.93 | +0.24% |
| Week 2 | $1.62 | $1.80 | $2.00 | +0.49% |
| Week 3 | $1.59 | $1.80 | $2.05 | +0.73% |
| Week 4 | $1.56 | $1.81 | $2.09 | +0.98% |
| Week 5 | $1.54 | $1.81 | $2.14 | +1.22% |
| Week 6 | $1.52 | $1.82 | $2.17 | +1.47% |
| Week 7 | $1.50 | $1.82 | $2.21 | +1.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada. It operates through its subsidiary enGene, Inc. and develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC).
Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026.
ENGN trades at $1.76 with a market capitalization of $117.9M and is ranked 3942.
The near-term technical picture is NEUTRAL, with a 30-day range of $1.41 to $2.19 and a current price around $1.76. The forecast offers a long-run bullish tilt, with the average price rising over time and sentiment upgrading from NEUTRAL in 2026 to BULLISH in subsequent years.
Year-by-year forecasts show an upward trajectory in Avg values—from $1.76 in 2026 to $3.21 by 2030, then higher into the 2040s and 2050s—accompanied by rising ROI figures. The projected sentiment turns BULLISH starting 2027 and stays bullish through 2050.
A major floor 19.6% below — a decisive break under it would weaken the trend.
The nearest floor, 5.6% below — buyers have tended to step in here.
The nearest ceiling, 7.8% above — a clean break opens room to run.
A major ceiling 394.4% above — clearing it would confirm fresh momentum.
Key ENGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.77 | Buy | $1.79 | Buy |
| MA 10 | $1.82 | Sell | $1.81 | Sell |
| MA 20 | $1.86 | Sell | $1.83 | Sell |
| MA 50 | $1.77 | Buy | $2.37 | Sell |
| MA 100 | $4.05 | Sell | $3.68 | Sell |
| MA 200 | $6.39 | Sell | $4.99 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.08 | Neutral |
| Stoch RSI (14) | 36.22 | Neutral |
| CCI (20) | -88.33 | Neutral |
| Williams %R (14) | -82.35 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -5.79 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 17.65 | Buy |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 42.38 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 1.75 | Buy |
| ADX (14) | 17.90 | Neutral |
| ATR (14) | 0.05 | Info |
Near term, the technical picture is NEUTRAL with RSI 14 at 40. The 50-day simple moving average is $1.76, while the 200-day simple moving average is $6.55. Support is at $1.62 and resistance at $1.93, framing a narrow zone around the current price. The 30-day range is $1.41 to $2.19, providing a defined near-term trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.44 | $1.79 | $2.50 | 0% | Neutral | |
| $2.03 | $2.55 | $3.38 | +42% | Bullish | |
| $2.09 | $2.70 | $3.72 | +51% | Bullish | |
| $2.23 | $2.95 | $4.20 | +65% | Bullish | |
| $2.38 | $3.21 | $4.68 | +79% | Bullish | |
| $2.28 | $3.14 | $4.68 | +76% | Bullish | |
| $2.53 | $3.55 | $5.38 | +98% | Bullish | |
| $2.92 | $4.16 | $6.43 | +132% | Bullish | |
| $3.30 | $4.78 | $7.51 | +167% | Bullish | |
| $3.74 | $5.49 | $8.75 | +207% | Bullish | |
| $4.65 | $7.33 | $12.44 | +309% | Bullish | |
| $7.71 | $13.66 | $25.40 | +663% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.44 | $1.79 | $2.21 | +0.00% |
| September 2026 | $1.58 | $1.87 | $2.28 | +4.67% |
| October 2026 | $1.55 | $1.85 | $2.27 | -1.38% |
| November 2026 | $1.58 | $1.90 | $2.35 | +2.58% |
| December 2026 | $1.66 | $2.00 | $2.50 | +5.65% |
Click any year to see its month-by-month ENGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ENGN price prediction for 2026 points to an average of $1.79 (low $1.44, high $2.50) — a potential gain of 0% on today's $1.79. A consolidation phase looks the most probable path here.
In 2027, ENGN is projected to trade between $2.03 and $3.38, averaging $2.55 — a potential gain of +42% from today's $1.79. That is up +42% on the projected 2026 average. Momentum favours further upside here.
enGene Therapeutics Inc.'s 2028 outlook centres on $2.70, within a $2.09 to $3.72 range. That is up +6% on the projected 2027 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ENGN could reach as high as $4.20, with a base case around $2.95 and support toward $2.23 — roughly +65% from $1.79. Momentum favours further upside here.
Expect ENGN to range from $2.38 to $4.68 through 2030. The $3.21 average target implies a +79% move from current prices. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ENGN price prediction for 2031 points to an average of $3.14 (low $2.28, high $4.68) — a potential gain of +76% on today's $1.79. Momentum favours further upside here.
In 2032, ENGN is projected to trade between $2.53 and $5.38, averaging $3.55 — a potential gain of +98% from today's $1.79. That is up +13% on the projected 2031 average. Buyers look set to stay in control over this stretch.
enGene Therapeutics Inc.'s 2033 outlook centres on $4.16, within a $2.92 to $6.43 range. That is up +17% on the projected 2032 average. That marks a +132% change versus current levels. Momentum favours further upside here.
By 2034, ENGN could reach as high as $7.51, with a base case around $4.78 and support toward $3.30 — roughly +167% from $1.79. Buyers look set to stay in control over this stretch.
Expect ENGN to range from $3.74 to $8.75 through 2035. The $5.49 average target implies a +207% move from current prices. That is up +15% on the projected 2034 average. Momentum favours further upside here.
The ENGN price prediction for 2040 points to an average of $7.33 (low $4.65, high $12.44) — a potential gain of +309% on today's $1.79. Buyers look set to stay in control over this stretch.
In 2050, ENGN is projected to trade between $7.71 and $25.40, averaging $13.66 — a potential gain of +663% from today's $1.79. That is up +86% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ENGN today (≈ 558.659218 ENGN) could be worth
$7,633.01
+$6,633.01 (+663%) by 2050 · US Dollar
Based on the average projected ENGN price of $13.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENGNwould be worth at today's price.
$1,000 invested in ENGN on Jul 31, 2025 (≈ 263.852245 ENGN) would be worth
$472.3
-$527.7 (-52.8%) today · 0.47× · US Dollar
Based on a ENGN entry price of $3.79 vs. today's $1.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.82 | $983.52 | -1.6% |
| 1 month ago | $1.76 | $1,017.05 | +1.7% |
| 3 months ago | $7.25 | $246.9 | -75.3% |
| 6 months ago | $10 | $179 | -82.1% |
| 1 year ago | $3.79 | $472.3 | -52.8% |
| All time (4.5y) ago | $9.86 | $181.54 | -81.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENGN forecast.
Our base-case forecast reaches $3.60 around 2033.
Implied market cap at $3.60: $241.16M
The multi-year forecast shows a steady bullish trajectory after 2026. In 2026 the avg is $1.76 with min $1.44 and max $2.55, and the ROI is 0 with NEUTRAL sentiment. From 2027 onward the path strengthens: 2027 avg $2.58 (min $2.02, max $3.52; ROI 46.7), 2028 avg $2.75 (min $2.07, max $3.91; ROI 56.2), 2029 avg $2.98 (min $2.19, max $4.40; ROI 69.5), 2030 avg $3.21 (min $2.29, max $4.87; ROI 82.5).
Beyond 2030, the forecast remains bullish: 2031 avg $3.10 (ROI 76.3), 2032 avg $3.50 (ROI 98.8), 2033 avg $4.17 (ROI 136.8), 2034 avg $4.88 (ROI 177.4), 2035 avg $5.61 (ROI 218.7). In the longer horizon, 2040 is projected at avg $7.41 (ROI 321.2) and 2050 at avg $13.63 (ROI 674.7). The sentiment across these later milestones is consistently BULLISH.
These are estimates and not guarantees, and actual results may differ.
Tap a question to reveal the answer.
2030 avg $3.21, min $2.29, max $4.87; ROI 82.5; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with avg rising to $2.58 in 2027, $3.21 by 2030, and $13.63 by 2050, with ROI reaching 674.7% by 2050. These are estimates, not guarantees.
The forecast max by 2050 is $27.23, with 2040 max $13.37 and 2035 max $9.42; a $10 level would be within the projected range, but these are estimates.
Low $1.41, high $2.19.
enGene Therapeutics Inc. Community Discussion
0Share your enGene Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.